Figure 3.
[89Zr]Zr-rituximab activity in the spleen using the non-preload protocol, between treatment outcomes: non-responder (NR) on the left and responder (RSP) on the right. There is significantly higher measurable splenic activity in the NR patient (arrow) and a slight bone marrow uptake. No particular adjustment is made on the scale bar to reflect the difference.